

The Dow/Karabatsos Distinguished Lectureship

The Dow/Karabatsos Lecture Series in the Chemical Sciences has enriched the experience of workers in the chemical sciences at MSU for over two decades. As is evident from the list of distinguished speakers, this lectureship has provided opportunities for students and faculty to interact with outstanding researchers from all areas of chemistry. We are grateful to Dow for their ongoing support that permits us to continue this tradition of extending invitations to outstanding scholars and teachers such as Professor David MacMillan. The Department has started an endowment for this lecture series in honor of Professor Gerasimos J. Karabatsos.

Previous Dow/Karabatsos Lecturers

1981	George A. Olah*
1982	Gabor A. Somorjai
1983	Allen J. Bard
1984	John H. Sinfelt
1985	Robert G. Bergman
1986	Paul von R. Schleyer
1987	Robert H. Grubbs*
1988	F. Albert Cotton
1989	Julius Rebek
1990	Tobin J. Marks
1991	Nicholas J. Turro
1992	Marye Anne Fox
1993	Richard H. Holm
1994	John I. Brauman
1995	Josef Michl
1996	JoAnne Stubbe
1997	Dale L. Boger
1998	Fred W. McLafferty
1999	Daniel G. Nocera
2000	K. C. Nicolaou
2001	Richard R. Schrock*
2002	Jean M.J. Fréchet
2003	Robert H. Grubbs*
2004	Galen D. Stucky
2005	Donald A. Tomalia Emmanuel P. Gianneli Andrew Ellington Joseph A. Caruso Larry R. Dalton
2006	Sidney M. Hecht
2007	John E. Bercaw
2008	Peter J. Stang

*Nobel Prize Winner



Dow/Karabatsos
Distinguished Lectureship
in the
Chemical Sciences

Presents

Professor
David W. C. MacMillan

Merck Center for Catalysis
at Princeton University
Princeton, New Jersey

Sponsored by:

The Dow Chemical Company
and the
MSU Department of Chemistry

December 10 and 11, 2009
MSU Chemistry Building

MICHIGAN STATE
UNIVERSITY



Lecture Topics

Thursday, December 10, 2009

4:20 pm, Room 138

**“New Organocatalysis
Concepts”**

Friday, December 11, 2009

4:10 pm, Room 136

**“Photoredox Catalysis in
Organic Chemical Synthesis”**

All lectures in the
Chemistry Building – MSU



Dave MacMillan received his undergraduate degree in chemistry at the University of Glasgow, where he worked with Dr. Ernie Colvin. In 1990, he left the U.K. to begin his doctoral studies under the direction of Professor Larry Overman at the University of California, Irvine. In 1996, he moved to a postdoctoral position with Professor Dave Evans at Harvard University where his studies centered on enantioselective catalysis. He began his independent career at University of California, Berkeley in July of 1998 before moving to the California Institute of Technology in June of 2000. In 2003, he was promoted to Full Professor at Caltech, before being appointed the Earle C. Anthony Chair of Organic Chemistry in 2004. In 2006, MacMillan moved to the east coast of the U.S. to take up a position at Princeton University as the A. Barton Hepburn Chair of Chemistry and Director of the Merck Center for Catalysis at Princeton

University. Professor MacMillan's research program is centered on chemical synthesis with specific interests in new reaction development, enantioselective organocatalysis and the rapid construction of molecular complexity.

He has received several awards including the Mukaiyama Award (2007), ISHC Award in Heterocyclic Chemistry (2007), ACS Cope Scholar Award (2007), Thieme–IUPAC Prize in Organic Synthesis (2006), Elias J. Corey Award for Outstanding Original Contribution in Organic Synthesis by a Young Investigator (2005), the Tetrahedron Young Investigator Award (2005), the Corday-Morgan Medal (2005), Henry Dreyfus Teacher-Scholar Award (2003), a Sloan Fellowship (2002), and a Woodward Scholarship Award from Harvard University (2001).

Dave is currently editor-in-chief of the new RSC journal *Chemical Sciences* and is a member of the *Chemical Communications*, *Tetrahedron*, *Tetrahedron Letters*, *Chemistry–an Asian Journal*, *Advances in Catalysis and Synthesis* editorial advisory boards. Dave is a co-founder of Chiromics LLC and is a member of the scientific advisory board of Lexicon Pharmaceuticals and a permanent member of the RSRC board (Chemistry SAB) at Merck. Dave is currently a scientific consultant with Merck (worldwide), Amgen (worldwide), Abbott Research Laboratories, Johnson & Johnson Pharmaceuticals, Constellation Pharmaceuticals and Gilead Research Laboratories.

While Dave has several hobbies, he enjoys drinking wine by far the most.